SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gains on launching generic Acticlate tablets in US

03 Nov 2017 Evaluate

Lupin is currently trading at Rs. 1069.50, up by 8.60 points or 0.76% from its previous closing of Rs. 1060.90 on the BSE.

The scrip opened at Rs. 1062.00 and has touched a high and low of Rs. 1070.35 and Rs. 1062.00 respectively. So far 6,677 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 920.00 on 21-Aug-2017.

Last one week high and low of the scrip stood at Rs. 1090.00 and Rs. 993.50 respectively. The current market cap of the company is Rs. 48,329.00 crore.

The promoters holding in the company stood at 46.80%, while Institutions and Non-Institutions held 40.05% and 13.14% respectively.

Lupin has launched Doxycycline Hyclate Tablets USP, 75 mg and 150 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB rated generic equivalent of Aqua Pharmaceuticals, LLC’s Acticlate Tablets, 75 mg and 150 mg. They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablets USP, 75 mg and 150 mg had annual sales of around USD 263 million in the US, as per IMS MAT June 2017.


Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2459.75 17.40 (0.71%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×